Biomea Fusion’s (BMEA) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Biomea Fusion (NASDAQ:BMEA) in a report released on Wednesday,Benzinga reports. D. Boral Capital currently has a $12.00 target price on the stock.

Other analysts also recently issued reports about the stock. Wall Street Zen upgraded shares of Biomea Fusion from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Rodman & Renshaw started coverage on shares of Biomea Fusion in a research report on Tuesday, January 13th. They issued a “buy” rating and a $8.00 price objective on the stock. Citigroup lifted their price objective on shares of Biomea Fusion from $6.00 to $7.00 and gave the company a “buy” rating in a research report on Friday, March 27th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Biomea Fusion in a research report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $9.57.

Biomea Fusion Stock Down 7.4%

Shares of NASDAQ:BMEA opened at $1.76 on Wednesday. The company has a market cap of $127.25 million, a PE ratio of -1.34 and a beta of -0.25. The company’s 50-day moving average price is $1.33 and its 200 day moving average price is $1.40. Biomea Fusion has a fifty-two week low of $0.87 and a fifty-two week high of $3.08.

Institutional Trading of Biomea Fusion

Hedge funds and other institutional investors have recently made changes to their positions in the stock. ADAR1 Capital Management LLC bought a new stake in shares of Biomea Fusion during the 4th quarter worth about $54,000. Jain Global LLC bought a new stake in shares of Biomea Fusion during the 4th quarter worth about $68,000. Barclays PLC raised its position in shares of Biomea Fusion by 1,731.0% during the 4th quarter. Barclays PLC now owns 59,013 shares of the company’s stock worth $73,000 after buying an additional 55,790 shares in the last quarter. State Street Corp raised its position in shares of Biomea Fusion by 17.8% during the 4th quarter. State Street Corp now owns 165,115 shares of the company’s stock worth $205,000 after buying an additional 25,000 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in shares of Biomea Fusion during the 3rd quarter worth about $39,000. 96.72% of the stock is currently owned by institutional investors.

Biomea Fusion Company Profile

Biomea Fusion, Inc (NASDAQ:BMEA) is a clinical‐stage biopharmaceutical company headquartered in Carlsbad, California. The company is dedicated to the discovery and development of small molecule therapies that target epigenetic regulators implicated in cancer. By leveraging a proprietary chemistry and drug discovery platform, Biomea Fusion aims to design precision medicines that modulate gene expression pathways involved in the initiation and progression of hematological malignancies and solid tumors.

The company’s lead clinical asset, BMF-219, is an orally bioavailable inhibitor of the menin–mixed‐lineage leukemia (MLL) protein–protein interaction.